News Related to Overall Response Rates

Related coverage linked through entity extraction aliases.

Adagene and Incyte Launch Clinical Collaboration for Muzastotug Combination in Colorectal Cancer

Apr 02, 2026

Adagene and Incyte will collaborate on a Phase 1 study combining muzastotug with INCA33890 for MSS colorectal cancer patients, beginning in 2026. The collaboration marks the second instance where Adagene's SAFEbody technology is paired with a PD-1-based bispecific. Muzastotug has shown encouraging response rates in combination with pembrolizumab in previous trials.

CAR T Therapy Shows High Remission Rates in Multiple Myeloma, Communication Improvements Reduce Risks

Feb 26, 2026

CAR T-cell therapy is delivering high remission rates for multiple myeloma patients, with improved handoff communication reducing infection risks. FDA-approved BCMA-targeting products show response rates from 72% to 98% in heavily pretreated patients.